7-Azaindole JAK1 Inhibitor Selectivity

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current JAK inhibitors, such as tofatinib, baricitinib, and ABT-494, have poor selectivity and cause significant clinical side effects like anemia, infection, and increased blood lipids, limiting their efficacy and safety for treating inflammatory diseases.

Innovation Solution

A 7-azaindole derivative with high selectivity as a JAK family inhibitor, specifically designed to target JAK1 with improved inhibitory activity compared to existing compounds, thereby reducing side effects and enhancing therapeutic efficacy.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If pan-JAK inhibitors (tofatinib, baricitinib, ABT-494) are used to treat inflammatory diseases, then anti-inflammatory effect is improved, but selectivity deteriorates causing significant side effects (anemia, infection, increased blood lipids)

Engineering Contradiction:

Improveanti-inflammatory efficacyVSAvoidside effects

Core Design Contradiction:

ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The patent segments the JAK family inhibition into selective JAK1 inhibition rather than pan-JAK inhibition. The compound is designed to specifically target JAK1 while sparing other JAK isoforms (JAK2, JAK3, TYK2), thereby maintaining anti-inflammatory efficacy while reducing off-target side effects associated with broad JAK family inhibition

Inventive Principle:

Principle #1Segmentation

Solution Approach 2:

The compound exhibits local quality in terms of selective inhibition - it demonstrates high inhibitory activity against JAK1 (IC50 = 1.8 nM) while showing minimal activity against other JAK isoforms. This selective local effect on JAK1 allows targeted anti-inflammatory action without the systemic side effects of pan-JAK inhibition

Inventive Principle:

Principle #3Local quality

2Object-affected harmful factors

If selective JAK1 inhibitor (ABT-494) is used to improve selectivity, then side effects are reduced, but clinical risk of increasing LDL persists

Engineering Contradiction:

Improveside effectsVSAvoidclinical risk detection

Core Design Contradiction:

Object-affected harmful factorsVSDifficulty of detecting and measuring

Solution Approach 1:

The patent introduces a novel chemical structure (7-azaindole derivative with specific substituent patterns) as an intermediary compound that mediates between JAK1 inhibition and side effect reduction. The specific molecular architecture (with substituents R1-R6 at defined positions) acts as a mediator to achieve selective JAK1 binding while avoiding the LDL elevation issue seen with ABT-494

Inventive Principle:

Principle #24Intermediary (Mediator)

3Reliability

If JAK3 is inhibited to treat autoimmune diseases, then immune response modulation is improved, but risk of infection increases due to JAK3's presence in lymphocytes

Engineering Contradiction:

Improveimmune response modulationVSAvoidinfection risk

Core Design Contradiction:

ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The patent extracts JAK1 inhibition from the broader JAK family inhibition approach. By specifically targeting only JAK1 and excluding JAK3 inhibition, the compound achieves immune response modulation through JAK1 selectivity while avoiding the lymphocyte-related infection risks associated with JAK3 inhibition

Inventive Principle:

Principle #2Taking out (Extraction)

Data Source

PatentUS12304910B2Janus kinase (JAK) family inhibitor, preparation of same, and applications thereof

Publication Date: 2025.05.20 JIANGSU VCARE PHARMATECH

AI summary

A 7-azaindole derivative having the structure of formula (I), a pharmaceutical composition containing the compound of formula (I), and uses of the compound in preparing a medicament for preventing or treating Janus kinase (JAK) family-related diseases, specifically, uses in preventing or treating inflammatory diseases related to protein tyrosine kinase.